Bain Capital Life Sciences Investors’s Arcutis Biotherapeutics ARQT Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,030,703	Closed	-$9.59M	–	26
2024 Q2	$9.59M	Sell	1,030,703 -980,984	-49%	-$8.87M	1.05%	16
2024 Q1	$19.9M	Sell	2,011,687 -988,313	-33%	-$7.38M	1.6%	15
2023 Q4	$9.69M	Hold	3,000,000	–	–	0.93%	18
2023 Q3	$15.9M	Hold	3,000,000	–	–	1.78%	14
2023 Q2	$28.6M	Hold	3,000,000	–	–	2.94%	12
2023 Q1	$33M	Hold	3,000,000	–	–	4.12%	9
2022 Q4	$44.4M	Hold	3,000,000	–	–	4.96%	6
2022 Q3	$57.3M	Hold	3,000,000	–	–	6.84%	4
2022 Q2	$63.9M	Sell	3,000,000 -979,292	-25%	-$20.1M	7.5%	4
2022 Q1	$76.6M	Hold	3,979,292	–	–	7.44%	3
2021 Q4	$82.5M	Hold	3,979,292	–	–	6.55%	4
2021 Q3	$95.1M	Hold	3,979,292	–	–	5.9%	6
2021 Q2	$109M	Hold	3,979,292	–	–	7.12%	5
2021 Q1	$115M	Hold	3,979,292	–	–	6.52%	3
2020 Q4	$112M	Hold	3,979,292	–	–	7.03%	3
2020 Q3	$117M	Hold	3,979,292	–	–	10.87%	2
2020 Q2	$120M	Hold	3,979,292	–	–	12.6%	2
2020 Q1	$119M	Buy	+3,979,292	New	+$107M	20.05%	2

Other funds holding ARQT

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bain Capital Life Sciences Investors's ARQT Position: Q3 2024 in Review

Bain Capital Life Sciences Investors sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 1,030,703 shares — an estimated $9.59M sold.

Bain Capital Life Sciences Investors first reported a position in ARQT in Q1 2020 and held it in 18 quarters. The position peaked at $120M in Q2 2020. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

Bain Capital Life Sciences Investors reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,030,703 Arcutis Biotherapeutics shares in Q3 2024, an estimated $9.59M.
Bain Capital Life Sciences Investors first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 18 quarters.
Bain Capital Life Sciences Investors's Arcutis Biotherapeutics position peaked at $120M in Q2 2020.
188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2024, filed 14 Nov 2024.